NuCana Reports Q3 2025 Financial Results and Board Resignation

Tip Ranks
2025.11.13 22:12
portai
I'm PortAI, I can summarize articles.

NuCana announced Q3 2025 financial results, reporting reduced operating losses of £779,000, down from £5.3 million in 2024, but still facing financial challenges with a comprehensive loss of £267,000. Additionally, Dr. Bali Muralidhar resigned from the Board, effective October 21, 2025, without disagreements. Spark rates NCNA as Underperform due to financial instability and negative valuation metrics, despite strong cash management. NuCana specializes in developing novel cancer treatments.